Mode
Text Size
Log in / Sign up

INSTI switching linked to higher metabolic risk in people with HIVSwitching HIV meds raises diabetes risk but not heart attack danger

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Switching to integrase inhibitors in people with HIV raises metabolic risks but not MACE over five years.

This retrospective cohort study, emulating a target trial, analyzed data from 5,114 people with HIV at low-to-moderate cardiovascular risk across 12 countries. The primary exposure was switching to an integrase strand-transfer inhibitor (INSTI) regimen, with the comparator being remaining on a non-INSTI regimen. The study followed participants for five years to assess the risk of incident obesity, diabetes, hypertension, and major adverse cardiovascular events (MACE).

The main findings indicated that switching to an INSTI was associated with a significantly higher risk of developing obesity, diabetes, and hypertension compared to staying on a non-INSTI regimen. For obesity, the hazard ratio (HR) was 1.41 (95% CI 1.22-1.59). For diabetes, the HR was 1.50 (95% CI 1.24-1.81). For hypertension, the HR was 1.45 (95% CI 1.26-1.67). These results suggest a consistent pattern of increased metabolic risk following a switch to INSTI therapy.

In contrast, the study found no significant effect on the risk of MACE, with an HR of 1.17 (95% CI 0.87-1.57). This indicates that while metabolic comorbidities may be elevated, the immediate cardiovascular event risk did not differ meaningfully between the groups over the five-year follow-up period.

The study's global setting and large sample size enhance the generalizability of these findings to diverse populations of people with HIV. However, the retrospective design and lack of reported absolute risk numbers are important limitations. The analysis did not account for all potential confounding factors, and the causality of the observed associations cannot be definitively established.

Funding was provided by several entities, including the National Institutes of Health and pharmaceutical companies such as Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare. These relationships warrant consideration when interpreting the results, though the study's design and execution were independent.

From a clinical practice perspective, these findings underscore the need for long-term monitoring of metabolic parameters in patients who switch to INSTI regimens. Clinicians should be vigilant for the development of obesity, diabetes, and hypertension, and consider proactive management strategies to mitigate these risks.

The study did not report on safety outcomes, such as adverse events or discontinuations, which limits a comprehensive assessment of the overall risk-benefit profile of INSTI switching. Future prospective studies are needed to confirm these observations and to explore the underlying mechanisms driving the increased metabolic risk.

In summary, this research highlights a trade-off in HIV management: while INSTIs are effective for viral suppression, their use may be associated with a higher burden of metabolic comorbidities. Careful patient selection and ongoing surveillance are essential to optimize long-term health outcomes.

Imagine you have been managing HIV for years. You feel stable. Your doctor tells you to switch your daily pill to a newer version. You agree because the new one works well. But what happens to your body over the next few years?

New research answers this question with surprising clarity. People who switch to a specific type of HIV medication face higher risks for weight gain and diabetes. The good news is that their risk for heart attacks does not go up.

Many people with HIV live long lives. They manage their virus well. But they often face other health problems. High blood pressure and diabetes are common issues. Doctors worry about these conditions because they hurt the heart.

Current treatments sometimes cause weight gain. Some older drugs also caused heart issues. Patients want to know if changing their medicine helps or hurts. This study looks at real-world data from twelve countries. It tracks thousands of people over five years.

The Old Way Vs New Way

Doctors used to avoid certain drugs because of side effects. They feared weight gain and heart problems. Now, a new class of drugs called integrase strand-transfer inhibitors is popular. These drugs work very well at stopping the virus.

But here is the twist. Switching to these drugs changes the metabolic picture. The body handles sugar and fat differently. This shift happens even if the virus stays under control. The study compares people who switched to these drugs against those who stayed on older regimens.

A Factory That Runs Hotter

Think of your cells as a factory. They process sugar and make energy. Sometimes this factory gets clogged or runs inefficiently. The new drugs seem to slow down the factory's ability to handle sugar. This leads to higher blood sugar levels.

High blood sugar is the definition of diabetes. It also leads to extra weight. The body stores fat when it cannot use sugar properly. This is like a traffic jam on a highway. Cars (sugar molecules) get stuck and pile up. The body then stores them as fat instead of using them for energy.

The researchers looked at over five thousand participants. They followed them for five years. The results were clear for three conditions. People who switched had a forty-one percent higher risk of obesity. Their risk for diabetes rose by fifty percent. The risk for high blood pressure jumped by forty-five percent.

These numbers sound scary. But they come from a large group. The study included people aged forty to seventy-five. Most were on stable treatment before the switch. They had a healthy immune system count. This makes the results very relevant for real patients.

This doesn't mean this treatment is available yet.

The study also looked at heart attacks. This is a major concern for older adults. The data showed no increase in heart attacks. The risk ratio was close to one. This means the switch did not make heart events more likely. Patients can breathe easier on this point.

If you are considering a switch, talk to your doctor. They will weigh the benefits against the risks. The new drugs are very effective at controlling the virus. This is the most important goal for everyone with HIV.

However, you must monitor your weight and blood sugar. Regular check-ups become even more important. Your doctor might suggest lifestyle changes. Eating well and moving your body can help manage these risks. Do not stop your medication without advice.

The Limitations

Every study has limits. This one used data from a large trial. It emulated a series of smaller trials. The group was mostly male. Women made up about one-third of the participants. The study also looked at people with low-to-moderate heart risk.

This means results might differ for others. People with very high heart risk were not included. The study also relied on past data. It could not control every lifestyle factor. Patients should see their own doctors for personal advice.

Doctors will watch these patients closely. Long-term observation is crucial. We need to know if heart risks rise later. More research will follow this initial finding. Scientists will look for ways to prevent weight gain. They might find new drugs that do not cause these issues.

For now, the message is balanced. The new drugs are powerful tools. They help people live longer and healthier lives. But they require careful management. Your healthcare team will guide you through the best choices.

Study Details

Study typeRct
Sample sizen = 5,114
EvidenceLevel 2
Follow-up900.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Integrase strand-transfer inhibitors (INSTIs) are linked to weight gain, but data on their cardiometabolic effects, particularly major adverse cardiovascular events (MACE), are scarce. We aimed to estimate the risk of obesity, diabetes, hypertension, and MACE after switching to an INSTI in people with HIV at low-to-moderate cardiovascular risk. METHODS: In this retrospective cohort study, we used data from the global Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) to emulate a series of trials comparing switching to an INSTI versus remaining on a non-INSTI regimen on risk of incident obesity, diabetes, hypertension, and MACE. The REPRIEVE trial collected data across 12 countries from participants aged 40-75 years, on a stable antiretroviral therapy regimen for at least 6 months, with a CD4 count of >100 cells per μL, and with low-to-moderate risk for atherosclerotic cardiovascular disease. From this cohort, we included participants without a previous diagnosis of the outcomes or previous INSTI use and used data for a follow-up period of 5 years, until the outcome event, loss to follow-up, death, or study end. Data from emulated trials were pooled and hazard ratios (HRs) were estimated with weighted Cox proportional hazard models, accounting for competing events. FINDINGS: 5114 participants met eligibility criteria for at least one emulated trial, representing 99 357 person-trials (median age 49 years [45-54]; 62 826 [63·2%] of 99 357 were male; 36 531 [36·8%] were female). 2981 (58·3%) of 5114 participants were captured as an INSTI switcher in at least one trial. Most switchers (2412 [80·9%] of 2981) initiated a dolutegravir-based regimen and most (47 263 [67·1%] of 70 458) non-switchers were on an efavirenz-based regimen. The HR of obesity (HR 1·41, 95% CI 1·22-1·59), diabetes (1·50, 1·24-1·81), and hypertension (1·45, 1·26-1·67) was higher in switchers than non-switchers. We did not observe an effect on MACE (1·17, 0·87-1·57). INTERPRETATION: The increase in cardiometabolic risk profile suggests long-term observation of people with HIV switching to INSTIs will be crucial to ensure appropriate management of comorbidities and to assess for future development of MACE. FUNDING: National Institutes of Health, Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.